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Abstract
Background: Despite the progress seen in the last decade in diagnosis and treatment, lung cancer has still a bad
prognosis and a substantial number of patients died within the weeks following diagnosis. The objective of this
study was to quantify early mortality in lung cancer, to identify patients who are at high risk of early decease, and
to describe their management in a real world.
Methods: Prospective observational study including consecutively all adult patients managed for primary lung
cancer histologically or cytologically diagnosed in 2010 in the respiratory medicine department of one of the
participating French general hospitals. Patients and cancer characteristics and first therapeutic strategy were
collected at diagnosis. Dates of death were obtained from investigators or town council of the patient’s birth place.
All fatal cases were considered regardless of the cause of the death. Multivariate logistic regression model was used
to determine the factors significantly and independently associated with death at 1 and 3 months.
Results: Seven thousand fifty-one patients from 104 centres were included in the study. Vital status was obtained
for 6,981 patients. Respectively, 678 (9.7 %) and 1,621 (23.2 %) of the 6,981 patients with available data died within
1 and 3 months following diagnosis. As compared with the other patients, they were significantly older and frailer
(based on performance status [PS] and recent weight loss) and more frequently reported stage IV tumour. Overall,
64.5 % (1 month) and 42.8 % (3 months) of patients had no cancer therapy and less than 1 % were included in a
therapeutic trial.
Conclusion: About one in four patients died within 3 months following lung cancer diagnosis. Early mortality
mainly involves frail patients with advanced cancer and is associated with lack of cancer therapy. This supports the
need for early diagnosis and clinical trials in this population. Reducing early mortality to give supplementary time to
patients to organise the future is a major challenge for 21st century physicians.
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Background
Despite the progress seen in the last decade in diagnosis
and treatment, lung cancer has still a bad prognosis [1].
In France, in 2010, 1-year mortality rate in patients with
lung cancer was estimated at 56 % [2].
Literature on lung cancer mortality is abundant. Be-
tween 01-January-2000 and 30-November-2015, more
than 8,000 articles with an abstract could be identified
when consulting PubMed with the following sentence:
‘lung neoplasms [Mesh]’ and ‘mortality [Mesh]’. How-
ever, available information about early mortality is lim-
ited [3]. Most of the literature relates to treatment and
usually excludes elderly, frail, and socially marginalised
patients [3], or tries to identify predictors of early mor-
tality after specific therapeutic interventions (e.g., surgi-
cal resection) or in specific populations (e.g., patients
with comorbidity).
In 2010, the French College of General Hospital
Respiratory Physicians (CPHG) conducted a prospective
observational study, KBP-2010-CPHG, whose main
objective was to assess 5-year mortality rate. This study
involved the respiratory medicine department of 119
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French general hospitals. Overall, 7,610 adults man-
aged with primary lung cancer histologically or cyto-
logically diagnosed between the 01-January-2010 and
31-December-2010 in the participating respiratory
medicine departments were included [4].
As a significant proportion of patients from the KBP-
2010-CPHG died just after the diagnosis of lung cancer,
a post hoc analysis was performed to (a) quantify early
mortality (1 and 3 months), (b) to identify the main
characteristics of patients who early died, and (c) to de-
scribe their management. From health care system and
professional perspectives, identifying patients who early
died and describing their management emphasize the
need for earlier diagnosis and palliative approaches and
for more effective treatment. From a patient or family
perspectives, they emphasize the need for more effective
treatment and improved support to save time and better
face this unfavourable outcome [5].
Methods
KBP-2010-CPHG is a French prospective multicentre
observational study. The study protocol was approved
by the advisory committee on research information pro-
cessing in the health field (CCTIRS) on 19 November
2009 and the French Information technology and free-
doms commission (CNIL) on 11 January 2010 (909479).
The ethics committee of the French Speaking Society of
Pneumology confirmed the observational nature of the
study on 23 April 2010 (N°2010-008). All included pa-
tients were duly informed of the study objectives and re-
quirements, and gave their oral consent before inclusion.
At the end of 2009, the members of the CPHG which
gathers the chest physicians of the respiratory depart-
ments of the French general hospitals (overseas depart-
ments and territories included) were contacted. Those
agreeing to participate became study investigators and
their respiratory medicine department a study centre.
Each investigator has to exhaustively include all patients
aged over 18 years managed in his/her respiratory medi-
cine department for a primary lung cancer histological or
cytological diagnosed with a sample collected between 1st
January and 31st December 2010. The date of sample was
considered to be the date of the diagnosis. Then, the in-
vestigator filled out an anonymous questionnaire compris-
ing items on the patient, his/her tumour, and its treatment
really performed. A steering committee assessed study
compliance [4, 6]. Vital status and date of death were ob-
tained by the investigator or town council of the patient’s
birth place at least 1-year after the date of diagnosis.
All fatal cases were considered regardless of the cause
of the death. Patients who were alive 1 and 3 months
after the diagnosis date were censured at this date. First,
data were described using mean and standard deviation
(mean [SD]) or frequency and percentage (number [%]).
At 1 and 3 months, Chi2-test or Fisher test (when Chi2-
test criteria were not respected) and Student t test and
analysis of variance (ANOVA) (for normal distributions)
or non-parametric tests (for non-normal distributions)
were used to compare died and alive patients in univari-
ate analyses. A multivariate logistic regression model
was used to determine the factors significantly and inde-
pendently associated with death at 1 and 3 months. Stat-
istical test results were considered significant at p < 0.05
(2-sided). Missing data were not replaced.
Results
Study follow-up and baseline characteristics of the study
population
A total of 119 respiratory medicine departments partici-
pated in the study and included 7,610 patients. Fifteen
(15) centres deemed to be non-exhaustive by the steer-
ing committee were excluded from the study analysis. In
addition, some patients were excluded from the study as
they presented with major protocol failures: i.e., no in-
formation on histological or cytological sampling, sam-
pling date outside of the recommended window, primary
lung cancer not confirmed at histology, or cancer
managed outside of the study centre. Finally, the
KBP-2010-CPHG analysis population included 7,051
patients (including 6,083 patients with non-small-cell
lung cancer [NSCLC]) from 104 centres.
Mortality rates within the 1st year following diagnosis
The vital status at 1 year and the date of death (for died
patients) were obtained for 6,981 patients. Respectively,
678 (9.7 %) and 1,621 (23.2 %) patients died within 1
and 3 months following diagnosis.
Characteristics of the patients according to their vital
status at 1 and 3 months
Main characteristics of patients according to their vital
status 1 and 3 months following diagnosis are presented
in Table 1.
Compared with other patients, patients who early died
were older (p < 0.001), although 7 (9.6 %) and 12 (16.4 %)
of the 73 patients aged 40 years or less died within 1
and 3 months following diagnosis, respectively.
Patients who early died were leaner than the other
patients (p < 0.001) and had more frequently lost weight
within the 3 months preceding the diagnosis (p < 0.001).
Of the 616 patients having lost 10 kg or more, 115 (18.7 %)
and 269 (43.7 %) died within 1 and 3 months.
Compared with other patients, patients who early died
more frequently had a poorer performance status (PS ≥ 2)
(p < 0.001).
No significant differences was observed between
early dead patients and other patients in smoking sta-
tus (p = 0.831 and p = 0.803 at 1 and 3 months,
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Table 1 Characteristics of the patients (N = 6,981) according to vital statusa (N = 6,981)
Vital status at
1 month 3 months
Alive Dead Alive Dead
N N = 6,303 N = 678 p-value N = 5,360 N = 1,621 p-value
Sex n = 6,303 n = 678 0.018 n = 5,360 n = 1,621 0.097
Men, n (%) 5,286 4,747 (75.3) 539 (79.5) 4,033 (75.2) 1,253 (77.3)
Women, n (%) 1,695 1,556 (24.7) 139 (20.5) 1,327 (24.8) 368 (22.7)
Age n = 6,303 n = 678 <0.001 n = 5,360 n = 1,621 <0.001
≤40 years, n (%) 73 66 (1.1) 7 (1.0) 61 (1.1) 12 (0.7)
41-50 years, n (%) 536 502 (8.0) 34 (5.0) 448 (8.4) 88 (5.4)
51-60 years, n (%) 1,876 1,730 (27.5) 146 (21.5) 1,519 (28.3) 357 (22.0)
61-70 years, n (%) 2,053 1,865 (29.6) 188 (27.7) 1,612 (30.1) 441 (27.2)
71-80 years, n (%) 1,713 1,530 (24.3) 183 (27.0) 1,260 (23.5) 453 (28.0)
>80 years, n (%) 730 610 (9.7) 120 (17.7) 460 (8.6) 270 (16.7)
Age (years) n = 6,303 n = 678 <0.001 n = 5,360 n = 1,621 <0.001
Mean (SD) 65.2 (11.2) 68.2 (11.7) 64.7 (11) 68.2 (11.7)
Median (Q1-Q3) 65 (57-74) 68 (60-78) 64 (57-73) 68 (60-78)
Body mass index (BMI; kg/m2) n = 5,974 n = 558 <0.001 n = 5,139 n = 1,393 <0.001









Weight loss within the last 3 months n = 6,154 n = 625 <0.001 n = 5,249 n = 1,530 <0.001
No, n (%) 3,143 2,985 (48.5) 158 (25.3) 2,717 (51.8) 426 (27.8)
Yes, n (%) 3,636 3,169 (51.5) 467 (74.7) 2,532 (48.2) 1,104 (72.2)
If yes n = 3111 n = 446 <0.001 n = 2,493 n = 1,064 <0.001
<5 kg, n (%) 1,489 1,340 (43.1) 149 (33.4) 1,141 (45.8) 348 (32.7)
5-10 kg, n (%) 1,452 1,270 (40.8) 182 (40.8) 1,005 (40.3) 447 (42.0)
≥10 kg, n (%) 616 501 (16.1) 115 (25.8) 347 (13.9) 269 (25.3)
Performance status at diagnosis n = 6,235 n = 672 <0.001 n = 5,299 n = 1,608 <0.001
0- Fully active, n (%) 1,885 1,855 (29.8) 30 (4.5) 1,765 (33.3) 120 (7.5)
1- Restricted in heavy physical work, n (%) 2,872 2,749 (44.1) 123 (18.3) 2,462 (46.5) 410 (25.5)
2- Up and about more than half the day, n (%) 1,273 1,103 (17.7) 170 (25.3) 812 (15.3) 461 (28.7)
3- In bed or sitting in a chair more than half the day, n (%) 685 460 (7.4) 225 (33.5) 231 (4.4) 454 (28.2)
4- In bed or in a chair all the time, n (%) 192 68 (1.1) 124 (18.5) 29 (0.6) 163 (10.1)
Smoking status n = 6,271 n = 668 0.831 n = 5,335 n = 1,604 0.803
Never-smoker, n (%) 752 679 (10.8) 73 (10.9) 583 (10.9) 169 (10.5)
Former-smoker, n (%) 2,776 2,516 (40.1) 260 (38.9) 2,124 (39.8) 652 (40.7)
Active-smoker, n (%) 3,411 3,076 (49.1) 335 (50.2) 2,628 (49.3) 783 (48.8)
Tobacco consumption (pack-years)b 5,893 n = 5,352 n = 541 0.003 n = 4,566 n = 1,327 <0.001
Mean (SD) 42.8 (21.3) 45.3 (22.4) 42.5 (21) 44.9 (22.8)
Median (Q1-Q3) 40 (30-50) 40 (30-55) 40 (30-50) 40 (30-54)
Tobacco duration (years)b 5,220 n = 4,763 n = 457 0.015 n = 4,067 n = 1,153 <0.001
Mean (SD) 37.4 (11.6) 38.7 (11.5) 37.2 (11.6) 38.5 (11.6)
Median (Q1-Q3) 40 (30-45) 40 (30-46) 39 (30-45) 40 (30-45)
a1 and 3 months after the diagnosis of primary lung cancer (date of diagnosis = date of histological or cytological sampling);
bSmokers (former or active) only
N or n: number of subjects; Q1-Q3: First and third quartiles; SD: standard deviation
Note: Significant p-value are in bold
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respectively), but among smokers (former or active), heavier
consumer tended to die prematurely (p = 0.003 and
p < 0.001, respectively).
Characteristics of the tumours according to patient’s vital
status at 1 and 3 months
Table 2 presents the main characteristics of the tumour
according to patients’ vital status 1 and 3 months follow-
ing diagnosis.
Compared with other patients, patients who early died
more frequently had small-cell lung cancer (SCLC) at 1
month (19.5 % versus 13.2 %, p < 0.001; mortality rate: 13.7
%) but not at 3 months (14.6 % versus 13.5 %, p < 0.001;
mortality rate: 24.6 %). Compared with other patients with
NSCLC, patients who early died more frequently had
large-cell carcinoma at 1 month (17.9 % versus 10.6 %,
p < 0.001; mortality rate: 15.4 %) and at 3 months
(10.2 % versus 14.9 %, p < 0.001; mortality rate: 30.8 %).
They less frequently had adenocarcinoma, squamous-cell
carcinoma, or other lung cancer.
EGFR-mutation tests were performed for 2,111 patients,
mainly patients who did not early died (p < 0.0001). When
explored, EGFR-mutation was less frequently reported in
early died patients than in the other patients (p = 0.058 at
1 month and p = 0.003 at 3 months). The tumour of 6
(3.0 %) and 23 (11.4 %) of the 202 explored patients died
within 1 and 3 months following diagnosis carried the
EGFR mutation.
Stage IV tumour was more frequent in patients who
early died than in the other patients. Respectively, 29
(2.6 %) and 73 (6.5 %) of the 1,129 patients with lung
cancer of stage IIB and over died within 1 and 3 months
following diagnosis.
Independent risk factors of early death
Multivariate analysis (Table 3) confirmed that impaired
performance status (PS > 0) (PS4: OR = 71.9 [41–130.28],
p < 0.001, at 1 month and OR = 44.23 [26.29–77.66], p <
0.001, at 3 months), advanced cancer (OR = 2.17 [1.24–
3.88], p = 0.008 and OR = 2.36 [1.49-3.92], p < 0.001, at 1
month and OR = 2.44 [1.68–3.56], p < 0.001 and OR =
3.66 [2.72–5.02], p < 0.001, at 3 months, for stage IIIB and
stage IV, respectively), weight loss within the 3 months
preceding diagnosis (OR = 1.4 [1.09–1.81, p < 0.01 at
1 month and OR = 1.54 [1.3–1.82], p < 0.001 at 3
months), and large-cell carcinoma (OR = 1.72 [1.23–
2.38], p = 0.001, at 1 month and OR = 1.33 [1.04–1.68],
p = 0.022, at 3 months) were independent risk-factors of 1
and 3-month mortality. Small-cell carcinoma was an inde-
pendent risk-factor of mortality at 1 month (OR = 1.39
Table 2 Characteristics of the tumour according to patients’ vital statusa (N = 6,981)
Vital status at
1 month 3 months
Alive Dead Alive Dead
N N = 6,303 N = 678 p-value N = 5,360 N = 1,621 p-value
Histology n = 6,303 n = 678 n = 5,360 n = 1,621
Small-cell carcinoma, n (%) 961 829 (13.2) 132 (19.5) <0.001 725 (13.5) 236 (14.6) 0.309
Adenocarcinoma, n (%) 3,221 2,944 (46.7) 277 (40.9) 0.004 2,482 (46.3) 739 (45.6) 0.632
Squamous-cell carcinoma, n (%) 1,875 1,733 (27.5) 142 (20.9) <0.001 1,488 (27.8) 387 (23.9) 0.002
Large-cell carcinoma, n (%) 786 665 (10.6) 121 (17.9) <0.001 544 (10.2) 242 (14.9) <0.001
Adenocarcinoma in situ, n (%) 77 72 (1.1) 5 (0.7) 0.444 67 (1.3) 10 (0.6) 0.045
Carcinoid tumour, n (%) 40 39 (0.6) 1 (0.2) 0.176b 38 (0.7) 2 (0.1) 0.011
Other, n (%) 111 102 (1.6) 9 (1.3) 0.679 86 (1.6) 25 (1.5) 0.095
Genomic mutation n = 6,237 n = 670 n = 5,301 n = 1,606
Explored, n (%) 2,111 1,969 (31.6) 142 (21.2) <0.001 1,685 (31.8) 426 (26.5) <0.001
If explored, n = 1806 n = 121 n = 1,555 n = 372
EGFR mutated, n (%) 202 196 (10.9) 6 (5.0) 0.058 179 (11.5) 23 (6.2) 0.003
Stage (7 edition) n = 6,264 n = 672 <0.001 n = 5,334 n = 1,602 <0.001
Stage ≤ IIB, n (%) 1,129 1,100 (17.6) 29 (4.3) 1,056 (19.8) 73 (4.6)
Stage IIIA, n (%) 934 905 (14.4) 29 (4.3) 845 (15.8) 89 (5.6)
Stage IIIB, n (%) 705 643 (10.3) 62 (9.2) 571 (10.7) 134 (8.4)
Stage IV, n (%) 4,168 3,616 (57.7) 552 (82.1) 2,862 (53.7) 1,306 (81.5)
a1 and 3 months after the diagnosis of primary lung cancer (date of diagnosis = date of histological or cytological sampling);
bFisher test (violation of Chi² test conditions)
N or n: number of subjects
Note: Significant p-value are in bold
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[1.03–1.87], p = 0.032) but a protective-factor at 3 months
(OR = 0.73 [0.58–0.92], p = 0.008). Finally, multivariate
analysis showed that female gender (OR = 0.69 [0.52–0.9],
p = 0.007) was an independent protective-factor of 1-
month mortality and old age (>70 years) (OR = 1.51 [95 %
CI: 1.11–2.08], p = 0.011) an independent risk-factor of 3-
month mortality.
Characteristics of the first therapeutic strategy according to
patient’s vital status and in dead patients at 1 and 3 months
Table 4 presents the main characteristics of the first
therapeutic strategy according to patients’ vital status at
1 and 3 months after diagnosis.
Compared with the other patients, patients who early
died less frequently received at least 1 cancer therapy
Table 3 Independent significant risk factors of deatha (N = 5,548) – Reduced model
1 month 3 months








51-70 years 1.18 [0.89; 1.59] 0.267
>70 years 1.51 [1.11; 2.08] 0.011
Sex
Men 4,179 1 1
Women 1,369 0.69 [0.52; 0.9] 0.007 0.86 [0.71; 1.04] 0.129
Weight loss within the 3 preceding months
No 2,545 1 1
Yes 3,003 1.4 [1.09; 1.81] 0.01 1.54 [1.3; 1.82] <0.001
Smoking status
Never-smoker 1
Former-smoker 1.38 [1.05; 1.83] 0.024
Active-smoker 1.36 [1.03; 1.81] 0.031
Performance status at diagnosis
0- Fully active 1,576 1 1
1- Restricted in heavy physical work 2,362 2 [1.27; 3.28] 0.004 1.82 [1.43; 2.34] <0.001
2- Up and about more than half the day 1,002 6.5 [4.14; 10.63] <0.001 5.07 [3.92; 6.6] <0.001
3- In bed or sitting in a chair more than half the day 496 20.2 [12.84; 33.15] <0.001 17.27 [12.93; 23.25] <0.001
4- In bed or in a chair all the time 112 71.9 [41; 130.28] <0.001 44.23 [26.29; 77.66] <0.001
Stage (7 edition)
Stage ≤ IIB 901 1 1
Stage IIIA 759 0.75 [0.38; 1.46] 0.397 1.17 [0.79; 1.74] 0.436
Stage IIIB 570 2.17 [1.24; 3.88] 0.008 2.44 [1.68; 3.56] <0.001
Stage IV 3,318 2.36 [1.49; 3.92] <0.001 3.66 [2.72; 5.02] <0.001
Histology
Adenocarcinoma 2,521 1 1
Small-cell carcinoma 758 1.39 [1.03; 1.87] 0.032 0.73 [0.58; 0.92] 0.008
Squamous-cell carcinoma 1,440 0.89 [0.66; 1.2] 0.454 0.91 [0.75; 1.11] 0.348
Large-cell carcinoma 586 1.72 [1.23; 2.38] 0.001 1.33 [1.04; 1.68] 0.022
Adenocarcinoma in situ 48 2.05 [0.45; 6.43] 0.275 1.59 [0.62; 3.64] 0.298
Carcinoid tumour 78 1.01 [0.36; 2.45] 0.983 1.01 [0.5; 1.95] 0.983
Other 117 1.44 [0.58; 3.13] 0.396 1.17 [0.63; 2.06] 0.601
aFor patients with primary lung cancer diagnosed 1 and 3 months ago (multivariate logistic regression model; reduced model)
CI: confidence interval; N: number of subjects; OR: odds ratio
Note: Significant p-value are in bold
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(curative surgery incl.) (p < 0.001). At least 1 cancer
treatment was prescribed in 35.5 % of patients who died
within 1 month and 57.2 % of patients who died within
3 months. Overall 14 patients who early (0.9 %) died
were included in a clinical trial. The first therapeutic
strategy was less frequently discussed during a multidis-
ciplinary meeting in patients who early died than in the
other patients (p < 0.001).
In patients who early died, radiofrequency was excep-
tional (≤0.2 %) and curative surgery rare (≤3 %). Radio-
therapy was infrequent (9.7 % and 18.5 % of patients
who died within 1 and 3 months, respectively) and
quasi-exclusively palliative (e.g., treatment of cerebral
metastasis). Patients with radiotherapy who died within
1 or 3 months had virtually no curative radiotherapy (0.0
and 0.6 %). Respectively, 27.6 % and 44.5 % of patients
who died within 1 and 3 months received chemotherapy.
Chemotherapy was palliative in almost all patients
(97.3 % and 97.9 %, respectively), and only 71 patients
received a targeted therapy. Respectively, 49.3 % and
35.9 % of patients who died within 1 and 3 months
received supportive care.
Characteristics of patients without cancer therapy
Of the 951 patients without cancer therapy, respectively,
437 (46.0 %) and 693 (72.9 %) were dead 1 and 3 months
after the diagnosis. The percentage of patients who re-
ceived no cancer therapy increased with increasing age,
PS, and tumour stage (Fig. 1).
The main characteristics of the 951 patients without
cancer treatment are presented in Table 5 according to
vital status at 1 and 3 months.
Compared with the other patients with no cancer ther-
apy, patients who early died were significantly younger
(p < 0.001), they more frequently reported recent weight
loss (p < 0.001), and more frequently reported a PS of 3 or
4 (p < 0.001). Respectively, 107 (82.3 %) and 130 (90.9 %)
of the 143 patients with PS4 died within 1 and 3 months.
Patients who early died more frequently had a small-cell
carcinoma and less frequently presented with squamous-
cell carcinoma (p < 0.001) than the other patients with no
cancer therapy. They also more frequently had a stage
IV tumour: respectively, 318 (54.5 %) and 549 (84.0 %)
of the 653 patients with stage IV tumour died within 1
and 3 months. The percentage of patients who early
Table 4 First therapeutic strategy according to patients’ vital statusa (N = 6,981)
Vital status at
1 month 3 months
Alive Dead Alive Dead
N = 6,303 N = 678 p-value N = 5,360 N = 1,621 p-value
At least one therapy n = 6,303 n = 678 n = 5,360 n = 1,621
Yes, n (%) 6,177 (98.0) 559 (82.4) 5,273 (98.4) 1,463 (90.3)
<0.001 <0.001
No, n (%) 126 (2.0) 119 (17.6) 87 (1.6) 158 (19.7)
At least one cancer therapy n = 6,303 n = 678 n = 5,360 n = 1,621
Yes, n (%) 5,789 (91.8) 241 (35.5) 5,102 (95.2) 928 (57.2)
<0.001 <0.001
No, n (%) 514 (8.2) 437 (64.5) 258 (4.8) 693 (42.8)
At least one cancer therapy, exclusively n = 6,303 n = 678 n = 5,360 n = 1,621
Yes, n (%) 5,740 (91.1) 225 (33.2) 5,084 (94.9) 881 (54.3)
<0.001 <0.001
No, n (%) 563 (8.9) 453 (66.8) 276 (5.1) 740 (45.7)
Included in a therapeutic trial n = 6,303 n = 678 n = 5,360 n = 1,621
Yes, n (%) 221 (3.5) 2 (0.3) 209 (3.9) 14 (0.9)
<0.001 <0.001
No, n (%) 6,082 (96.5) 676 (99.7) 5,151 (96.1) 1,607 (99.1)
Multidisciplinary meeting n = 6,296 n = 671 n = 5,355 n = 1,612
Yes, n (%) 6,011 (95.5) 488 (72.7) 5,139 (96.0) 1,360 (84.4)
<0.001 <0.001
No, n (%) 285 (4.5) 183 (27.3) 216 (4.0) 252 (15.6)
a1 and 3 months after the diagnosis of primary lung cancer (date of diagnosis = date of histological or cytological sampling)
N or n: number of subjects
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died rose with PS and tumour stage increase but not
with age increase.
Discussion
The results of this study showed that in 2010, in France,
about 1 to 10 patients managed for primary lung cancer
in the respiratory department of a general hospital died
within 1 month and about 1 to 4 died within 3 months
after lung cancer diagnosis. They also showed that pa-
tients who died within 1 or 3 months following lung
cancer diagnosis were older and frailer (based on PS and
weight loss before diagnosis) than the other patients and
more frequently had a lung cancer at advanced stage. Fi-
nally, they pointed out that most of these patients had
no cancer therapy and most of patients without cancer
therapy early died.
Quantification of early death
To the best of our knowledge, this study is one of the
first aimed to evaluate the percentage of patients with
lung cancer who early died in clinical practice regardless














































Percentage of patients without cancer therapy according to tumour stage at diagnosis
Fig. 1 Percentage of patients without cancer therapy according to age, performance status, and tumour stage
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Table 5 Characteristics of patients without cancer therapy according to their vital statusa (N = 951)
Vital status at
1 month 3 months
Alive Dead Alive Dead
N N = 514 N = 437 p-value N = 258 N = 693 p-value
Sex n = 514 n = 437 0.071 n = 258 n = 693 0.911
Men, n (%) 733 384 (74.7) 349 (79.9) 200 (77.5) 533 (76.9)
Women, n (%) 218 130 (25.3) 88 (20.1) 58 (22.5) 160 (23.1)
Age n = 514 n = 437 <0.001c n = 258 n = 693 <0.001
≤40 years, n (%) 1 0 (0) 1 (0.2) 0 (0) 1 (0.1)
41-50 years, n (%) 31 14 (2.7) 17 (3.9) 4 (1.6) 27 (3.9)
51-60 years, n (%) 135 54 (10.5) 81 (18.5) 24 (9.3) 111 (16.0)
61-70 years, n (%) 216 101 (19.6) 115 (26.3) 46 (17.8) 170 (24.5)
71-80 years, n (%) 302 179 (34.8) 123 (28.1) 101 (39.1) 201 (29.0)
>80 years, n (%) 266 166 (32.3) 100 (22.9) 83 (32.2) 183 (26.4)
Age n = 514 n = 437 <0.001 n = 258 n = 693 <0.001
Mean (SD) 74.2 (10.9) 70.1 (11.4) 75 (9.9) 71.3 (11.7)
Median (Q1-Q3) 76.5 (67-82) 71 (61-80) 77 (69-82) 72 (62-81)
Body mass index (BMI; kg/m2) n = 414 n = 337 0.863 n = 221 n = 530 0.015
Mean (SD) 23.6 (5.1) 23.5 (4.7) 24.4 (5.4) 23.2 (4.6)
Median (Q1-Q3) 23.1 (20.1-26.8) 23.4 (20.2-26.4) 24 (20.6-27.4) 23 (19.9-26.2)
Weight loss within the last 3 months n = 490 n = 394 <0.001 n = 249 n = 635 <0.001
No, n (%) 279 183 (37.3) 96 (24.4) 115 (46.2) 164 (25.8)
Yes, n (%) 605 307 (62.7) 298 (75.6) 134 (53.8) 471 (74.2)
If yes, n = 298 n = 282 0.224 n = 130 n = 450 0.010
<5 kg, n (%) 193 108 (36.2) 85 (30.1) 56 (43.1) 137 (30.4)
5-10 kg, n (%) 233 118 (39.6) 115 (40.8) 56 (43.1) 177 (39.3)
≥10 kg, n (%) 154 72 (24.2) 82 (29.1) 18 (13.8) 136 (30.2)
Performance status at diagnosis n = 511 n = 433 <0.001 n = 255 n = 689 <0.001
0- Fully active, n (%) 65 54 (10.6) 11 (2.5) 42 (16.5) 23 (3.3)
1- Restricted in heavy physical work, n (%) 179 120 (23.5) 59 (13.6) 78 (30.6) 101 (14.7)
2- Up and about more than half the day, n (%) 221 127 (24.8) 94 (21.7) 59 (23.1) 162 (23.5)
3- In bed or sitting in a chair more than half the day, n (%) 336 174 (34.1) 162 (37.4) 63 (24.7) 273 (39.6)
4- In bed or in a chair all the time, n (%) 143 36 (7.0) 107 (24.7) 13 (5.1) 130 (18.9)
Smoking status n = 505 n = 427 0.389 n = 252 n = 680 0.174
Never-smoker, n (%) 121 69 (13.7) 52 (12.2) 37 (14.7) 84 (12.4)
Former-smoker, n (%) 399 223 (44.2) 176 (41.2) 116 (46.0) 283 (41.6)
Active smoker, n (%) 412 213 (42.2) 199 (46.6) 99 (39.3) 313 (46.0)
Tobacco consumption (pack-years) b n = 394 n = 331 0.822 n = 198 n = 527 0.025
Mean (SD) 47.2 (26.3) 46.1 (22.4) 50 (27.3) 45.5 (23.4)
Median (Q1-Q3) 45 (30-60) 42 (30-59) 50 (30-60) 42 (30-55)
Tobacco duration (years) b n = 340 n = 280 0.016 n = 172 n = 448 0.012
Mean (SD) 41.9 (13.5) 39.7 (12) 42.9 (14.1) 40.1 (12.3)
Median (Q1-Q3) 40 (31.8-50) 40 (30-50) 43 (35-50) 40 (30-50)
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It shows that a significant proportion of patients died
within 1 (9.7 %) or 3 months (23.2 %) following dia-
gnosis. In the comparable KBP-2000-CPHG study,
performed 10 years ago in French general hospitals, the
3-month mortality was very close (22.1 %) indicating the
lack of improvement in 10 years. However, 3-month
mortality rate in our study was lower than that recently
reported by O’Dowd et al. in UK [3], 30 %. The 3-month
mortality among patients with inoperable non-small cell
lung cancer who developed respiratory failure was also
reported in a retrospective study and was very high in
this population (94.4 %) [5].
Main characteristics of patients who early died
Univariate analyses showed that patients who early died
had greater PS, lower BMI, and greater recent weight
loss than the other patients. Patients also more fre-
quently reported stage III or IV cancer. Age, sex, PS,
histology type, and cancer stage were included in the 4-
year mortality score developed and validated in 2006
using data from KBP-2000-CPHG study [7].
In the present study, we included recent weight loss.
In the literature, weight loss (>10 %) is a well-known
bad prognostic factor [8, 9]. Our results tended to indi-
cate that weight loss was a risk factor of early death and
also possibly a warning factor.
Early mortality did not seem to depend on sex and
was poorly associated with histology type. Small-cell car-
cinoma was an independent risk-factor of mortality at 1
month but a protective-factor at 3 months. This appar-
ent discrepancy possibly reflects the good initial re-
sponse to chemotherapy of small-cell lung cancers [10].
All in all, the most important parameter in early mortal-
ity is probably the cancer therapy that is actually per-
formed, in particular chemotherapy, and PS at diagnosis
which determines treatment [11, 12].
In the recent UK study by O’Dowd et al. [3], high rate
of pre-diagnosis consultations, social deprivation and
rural residence are associated factors with early death.
These indicators were not registered in our study.
Patients who early died usually did not receive cancer
therapy
Most of the patients who early died did not receive any
specific cancer therapy, especially the oldest. Patients
who early died more frequently had tumour at advanced
stage and non-operable status. They get less curative
treatment (surgery, radiofrequency, radiotherapy) and
more palliative treatment (chemotherapy, radiotherapy).
Despite the French National Cancer Institute developed
in 2010 a national program for mutation screening in
lung cancer giving us result in 7 days (4 to 25 days), this
population get less mutation screening and targeted
therapy prescribed. Also, clinical trial access was lower.
However, these patients benefits from a multidisciplinary
meeting discussion as well as the others. The youngest
patients get more than the oldest a cancer treatment.
Table 5 Characteristics of patients without cancer therapy according to their vital statusa (N = 951) (Continued)
Histology n = 514 n = 437 n = 258 n = 693
Small-cell carcinoma, n (%) 101 26 (5.1) 75 (17.2) <0.001 5 (1.94) 96 (13.9) <0.001
Adenocarcinoma, n (%) 394 215 (41.8) 179 (41.0) 0.838 96 (37.2) 298 (43.0) 0.124
Squamous-cell carcinoma, n (%) 297 201 (39.1) 96 (22.0) <0.001 117 (45.4) 180 (26.0) <0.001
Large-cell carcinoma, n (%) 155 70 (13.6) 85 (19.5) 0.019 38 (14.7) 117 (16.9) 0.483
Adenocarcinoma in situ, n (%) 5 2 (0.4) 3 (0.7) 0.855 2 (0.8) 3 (0.4) 0.885c
Carcinoid tumour, n (%) 3 2 (0.4) 1 (0.2) 1.000c 1 (0.4) 2 (0.3) 1.000c
Other, n (%) 11 7 (1.4) 4 (0.9) 0.736 3 (1.2) 8 (1.2) 1.000c
Genomic mutation n = 508 n = 430 n = 254 n = 684
Explored, n (%) 195 110 (21.7) 85 (19.8) 0.530 55 (21.7) 140 (20.5) 0759
If explored, n = 102 n = 76 n = 50 n = 128
EGFR mutated, n (%) 12 8 (7.84) 4 (5.26) 0.706 4 (8) 8 (6.3) 0.932
Stage (7 edition) n = 502 n = 432 <0.001 n = 252 n = 682 <0.001
Stage ≤ IIB, n (%) 94 79 (15.7) 15 (3.5) 65 (25.8) 29 (4.3)
Stage IIIA, n (%) 99 75 (15.0) 24 (5.6) 50 (19.8) 49 (7.2)
Stage IIIB, n (%) 88 51 (10.2) 37 (8.6) 33 (13.1) 55 (8.1)
Stage IV, n (%) 653 297 (59.2) 356 (82.4) 104 (41.3) 549 (80.5)
a1 and 3 months after the diagnosis of primary lung cancer (date of diagnosis = date of histological or cytological sampling);
bsmokers (former or active) only;
cFisher test as Chi2-test conditions were not respected
N or n: number of subjects; Q1-Q3: First and third quartiles; SD: standard deviation
Note: Significant p-value are in bold
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Probably because patients were old and had a higher
PS (3 or 4), clinicians are helpless. Treatment options
cannot easily be used in such patients in particular when
they presented with stage III or IV cancer. The decrease
in the percentage of patients with cancer therapy with
increasing age, PS, and stage confirms this hypothesis.
What would be the room for improvement?
Prevention, in particular through smoking cessation
campaigns, and lung cancer screening are the keys for
improving lung cancer mortality rate. Early diagnosis is
the key for reducing time to diagnosis and time to treat-
ment and, then, is for great importance to improve early
mortality. It can give the patients a chance to get a sys-
temic treatment before deterioration of the general con-
dition (better PS, early stage tumour, less weight loss).
Also, it can give the old and frail patients and their fam-
ily a chance to organise the future. Therefore, physicians
should pay attention to the smokers with increased re-
spiratory symptoms and recent weight loss and, rapidly
refer to a thoracic oncologist. Reducing early post-
operative mortality is for need depending on the resec-
tion type (lobectomy versus pneumonectomy, sleeve
lobectomy) and the team experience [13]. There is a
need for clinical research or trial on the patients with
bad prognostic factor (PS, tumour stage, age) and devel-
opment on palliative care treatment [14]. Lung cancer
mutation screening is for great importance in all stages
or PSs to give access to targeted therapy even or espe-
cially in the poor prognostic population who pays a
heavy price to early mortality.
Strengths and limitations
This study uses a large dataset (7,051 included patients,
about 20 % of all lung cancers diagnosed in France in
2010) and gives a true reflect of the lung cancer early
mortality in a real-world in France in 2010. However,
this is not a registry. This study gives us a view on the
management of lung cancer in the general hospital, only.
But general hospitals supports about 40–45 % of lung
cancer in France. The data completeness was checked as
described before [6].
In this analysis, we did not separate NSCLC and SCLC
which influence the mortality because we focused on the
timing, not on the histology type. In fact, from the clin-
ician point of view, the main problem is that the patient
fulfils poor prognostic factors and that he/she has to im-
prove patient’s quality of life and life expectancy.
Finally, the cause of death was unknown but lung can-
cer was probably the main cause regarding the short
interval after diagnosis, the severity of the disease, and
the low influence from smoking status. In this study,
surgery is pooled with other treatments. However, cura-
tive surgery was rare in patients who early died (≤3 %).
In addition, we found (data not shown) that 1- and 3-
month mortality rates in operated subjects (1.4 % and
3.7 %) were lower than in non-operated subjects (11.4 %
and 27.2 %), indicating that perioperative deaths do not
explain early mortality. We did not have information on
the metastatic site (brain) which could have an influence
on the early mortality as well as the site of the palliative
radiotherapy performed [12].
Conclusions
About 10 % of patients with lung cancer deceased within
the month following the diagnosis (date of sampling)
and 25 % within 3 months. As compared with the other
patients, patients who early died were older and frailer
(greater PS and recent weight loss) and more frequently
presented with stage IV tumour. Also, they presented
more frequently with a large-cell or small-cell carcinoma
and were less EGFR mutant. Most of these patients did
not receive any cancer therapy, probably because clini-
cians are helpless. There is a need to improve early diag-
nosis to give the patients a chance to receive a systemic
treatment to reduce early mortality and/or to give time
to the patients and his/her family to organise the future.
Indeed, there is a paucity of clinical data guiding the
management of clinicians due to the underrepresenta-
tion in clinical trials of old and frail patients. Specific
clinical trials using new drugs (targeted therapies) or
new therapeutic strategies in old and/or frail patients
must be implemented.
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